The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands
The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands
复制标题
DOI：
10.1016/j.vaccine.2007.11.070
复制
发表时间：
2008-02-20
期刊：
影响因子：
5.5
通讯作者：
Al, Maiwenn J.
中科院分区：
文献类型：
--
作者：
Goossens, Lucas M. A.;Standaert, Baudouin;Al, Maiwenn J.
本研究的目的是评估荷兰0-4岁儿童大规模接种Rotarix（TM）疫苗的成本效用。我们使用马尔可夫过程与荷兰的发病率，资源使用和成本（GP，住院，生产力损失和家庭成本）的数据，从社会角度比较疫苗接种和传统治疗。使用EQ 5D测量轮状病毒引起的腹泻导致的效用损失，全科医生和儿科医生作为代理人填写问题。由于每名儿童接种一个疗程的费用在90至100美元之间，因此每获得一个质量调整生命年的成本效用比在21，900至35，076美元之间。根据目前的研究，很明显，从经济和卫生保健的角度来看，大规模接种Rotorix（TM）预防轮状病毒胃肠炎是有吸引力的。(c)2007爱思唯尔有限公司保留所有权利。
The objective of this study was to estimate the cost-utility of mass vaccination of 0-4-year-old children with Rotarix (TM) in the Netherlands. We used a Markov process with Dutch data on incidence, resource use and costs (GP, hospitalisation, productivity loss and household costs) to compare vaccination to conventional treatment from a societal perspective. Utility toss due to rotavirus-induced diarrhoea was measured using EQ5D, with GPs and paediatricians serving as proxies to fill out the questions. As the costs of a vaccination course ranged from (sic)90 to (sic)100 per child, the cost-utility ratio varied from (sic)21,900 to (sic)35,076 per QALY gained. Based on the current study, it is clear that mass vaccination with Rotorix (TM) against rotavirus gastroenteritis can be attractive, from an economic and a health care perspective. (c) 2007 Elsevier Ltd. All rights reserved.